The second generation of Bcr-Abl inhibitors nilotinib, dasatinib, and bosutinib developed to override imatinib resistance are not active against the T315I “gatekeeper” mutation. Here we describe a ...

Ortex data shows short interest in Enliven Therapeutics had hovered between 24% and 29% since October 2023.